Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sales and regulatory review.
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment.
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.
